R&D and Innovation
Driven by independent innovation, continuously building a differentiated R&D pipeline for metabolic and chronic diseases
Explore Gan & Lee's scientific presentations at conferences worldwide, including abstracts, oral presentations, posters, and other related scientific materials.
Scientific Conferences
-
28th Annual Scientific Meeting of the Chinese Diabetes Society
28th Annual Scientific Meeting of the Chinese Diabetes Society · CDS 2026
Upcoming Conferences -
ObesityWeek
ObesityWeek · OW 2026
Upcoming Conferences -
62nd Annual Meeting of the European Association for the Study of Diabetes
62nd Annual Meeting of the European Association for the Study of Diabetes · EASD 2026
View Conference Materials -
23rd Annual Scientific Meeting of the Chinese Society of Endocrinology
23rd Annual Scientific Meeting of the Chinese Society of Endocrinology CSE 2026
View Conference Materials -
86th Scientific Sessions of American Diabetes Association
American Diabetes Association's 86th Scientific Sessions · ADA 2026
View Conference Materials -
27th Annual Scientific Meeting of the Chinese Diabetes Society
27th Annual Scientific Meeting of the Chinese Diabetes Society · CDS 2025
View Conference Materials -
ObesityWeek
ObesityWeek OW 2025
View Conference Materials -
61st Annual Meeting of the European Association for the Study of Diabetes
61st Annual Meeting of the European Association for the Study of Diabetes · EASD 2025
View Conference Materials -
85th Scientific Sessions of American Diabetes Association
American Diabetes Association's 85th Scientific Sessions · ADA 2025
View Conference Materials -
26th Annual Scientific Meeting of the Chinese Diabetes Society
26th Annual Scientific Meeting of the Chinese Diabetes Society · CDS 2024
View Conference Materials -
ObesityWeek
ObesityWeek OW 2024
View Conference Materials -
60th Annual Meeting of the European Association for the Study of Diabetes
60th Annual Meeting of the European Association for the Study of Diabetes · EASD 2024
View Conference Materials -
84th Scientific Sessions of American Diabetes Association
American Diabetes Association's 84th Scientific Sessions · ADA 2024
View Conference Materials -
59th Annual Meeting of the European Association for the Study of Diabetes
59th Annual Meeting of the European Association for the Study of Diabetes · EASD 2023
View Conference Materials -
International Diabetes Federation Virtual Congress 2023
International Diabetes Federation Virtual Congress 2023 IDF Virtual Congress 2023
View Conference Materials -
57th Annual Meeting of the European Association for the Study of Diabetes
57th Annual Meeting of the European Association for the Study of Diabetes EASD 2021
View Conference Materials
Pharmacokinetic and Pharmacodynamic Properties of Novel Once-Weekly Insulin GZR4 versus Insulin Degludec in Patients with Type 2 Diabetes
Insulin Ludefen(GZR4) · Phase I
Superior glycaemic control with once-weekly insulin GZR4 versus once-daily insulin glargine U100 in insulin-naïve type 2 diabetes: SUPER-1
Insulin Ludefen(GZR4) · Phase 3
Superior glycaemic control with once-weekly insulin GZR4 versus once-daily insulin degludec in adults with basal insulin-treated type 2 diabetes: SUPER-2
Insulin Ludefen(GZR4) ·Phase 3
Pharmacodynamic properties of novel once-daily insulin GZR33 in people with type 1 diabetes
GZR33 · Phase 1
Pharmacokinetic and Pharmacodynamic Profiles of GZR102 Injection, a Novel Once-Weekly Fixed-Ratio Combination of Insulin GZR4 and GLP-1 Analog Bofanglutide
GZR102 ·Preclinical
Effect of Bofanglutide on the Pharmacokinetics of Metformin in Healthy Participants
Bofanglutide (GZR18) · Phase 1
Effect of Renal Impairment on the Pharmacokinetics and safety of Bofanglutide.
Bofanglutide (GZR18) · Phase 1
Effects of Renal Impairment on the Pharmacokinetics and Safety of Bofanglutide
Bofanglutide (GZR18) · Phase 1
Effects of Bofanglutide on the Pharmacokinetics of Metformin
Bofanglutide (GZR18) · Phase 1
GZR102 Injection: A Study on the Pharmacokinetic and Pharmacodynamic Characteristics of a Novel, Once-weekly, Fixed-ratio Combination Drug Product of Insulin and a GLP-1 Analog
GZR102· Preclinical
Effects of Mild to Moderate Renal Impairment on the Pharmacokinetics and Safety of the Once-weekly Insulin Drug Product GZR4
Insulin Ludefen (GZR4) · Phase 1
Effect of Renal Impairment on the Pharmacokinetics and safety of Bofanglutide.
Bofanglutide (GZR18) · Phase 1
Effect of Bofanglutide on the Pharmacokinetics of Metformin in Healthy Participants
Bofanglutide (GZR18) · Phase 1
Pharmacokinetic and Pharmacodynamic Profiles of GZR102 Injection, a Novel Once-Weekly Fixed-Ratio Combination of Insulin GZR4 and GLP-1 Analog Bofanglutide
GZR102 · Preclinical
Effects of Moderate Renal Impairment on Pharmacokinetics and Safety of Once-weekly Insulin GZR4
Insulin Ludefen (GZR4) · Phase 1
Safety, Tolerability, and Pharmacokinetic Characteristics of GZR102 Injection Compared with GZR4 or Bofanglutide
GZR102 · Phase 1
A Comparison Study on the Efficacy and Safety of Bofanglutide Injection, a Bi-Weekly GLP-1 Receptor Agonist Drug Product and Semaglutide Injection in Adult Chinese Patients with Type 2 Diabetes Mellitus
Bofanglutide (GZR18) · Phase 2b Glycemic Control
Once-weekly GZR4 Injection Achieves Comparable HbA1c Reduction to Once-daily Insulin Degludec Injection in Insulin-naïve Adult Chinese Participants with Type 2 Diabetes Mellitus
Insulin Ludefen (GZR4) · Phase 2-A
Once-weekly GZR4 Injection Achieves Superior HbA1c Reduction to Once-daily Insulin Degludec Injection in Adult Chinese Participants with Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin
Insulin Ludefen (GZR4) · Phase 2-B
Efficacy and Safety of Bofanglutide (GZR18), a Biweekly GLP-1RA, Compared with Semaglutide in Chinese Patients with T2D
Bofanglutide (GZR18) · Phase 2b Glycemic Control
Superior Glycemic Control Achieved with Once-Weekly Insulin GZR4 Compared with Once-Daily Insulin Degludec in Insulin-Treated Chinese Subjects with T2D
Insulin Ludefen (GZR4) · Phase 2-B
Comparable Glycemic Control of Once-Weekly Insulin GZR4 Relative to Once-Daily Insulin Degludec in Insulin-Naïve Chinese Subjects with T2D
Insulin Ludefen (GZR4) · Phase 2-A
Bofanglutide (GZR18), a Novel GLP-1RA, Improved Glycemic Control and Cardiometabolic Risk Factors in Chinese Patients with T2D
Bofanglutide (GZR18) · Phase 1b/2a Glycemic Control
Efficacy and Safety of Bofanglutide (GZR18), a Biweekly GLP-1RA, Compared with Semaglutide in Chinese Patients with T2D
Bofanglutide (GZR18) · Phase 2b Glycemic Control
Superior Glycemic Control Achieved with Once-Weekly Insulin GZR4 Compared with Once-Daily Insulin Degludec in Insulin-Treated Chinese Subjects with T2D
Insulin Ludefen (GZR4) · Phase 2-B
Comparable Glycemic Control of Once-Weekly Insulin GZR4 Relative to Once-Daily Insulin Degludec in Insulin-Naïve Chinese Subjects with T2D
Insulin Ludefen (GZR4) · Phase 2-A
Novel GLP-1 Analog GZR18 Injection Resulted in 18.6% Weight Reduction in Participants with Obesity in a Phase Ib/IIa Clinical Trial
Bofanglutide (GZR18) · Phase 1b/2a Weight Reduction
Pharmacokinetic and Pharmacodynamic Characteristics of the Novel Once-weekly Insulin Drug Product GZR4 in Patients with Type 2 Diabetes Mellitus
Insulin Ludefen (GZR4) · Phase Ib
Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Characteristics of the Innovative Once-weekly Insulin Drug Product GZR4 in Healthy Chinese Participants
Insulin Ludefen (GZR4) · Phase Ia
Pharmacokinetic and pharmacodynamic properties of a novel once-weekly insulin analogue GZR4 in people with type 2 diabetes
Insulin Ludefen (GZR4) · Phase Ib
Safety, tolerability, and pharmacodynamic properties of a novel once-weekly insulin GZR4 in healthy subjects
Insulin Ludefen (GZR4) · Phase Ia
A Novel premix Insulin GZR101 for Diabetes Management
GZR101 · Preclinical
Molecular and Pharmacological Properties of GZR4, a Once Weekly Insulin Analog
Insulin Ludefen (GZR4) · Preclinical
A novel GLP-1 analog, GZR18, induced an 18.6% weight reduction in subjects with obesity in a phase Ib/IIa trial
Bofanglutide (GZR18) · Phase 1b/2a Weight Reduction
Efficacy, safety, and immunogenicity of proposed biosimilar Gan & Lee insulin glargine versus EU-licensed insulin glargine in patients with type 1 diabetes
Basalin · Phase 3 Type 1 diabetes mellitus
Efficacy, safety, and immunogenicity of proposed biosimilar Gan & Lee insulin glargine versus EU-licensed insulin glargine in patients with type 2 diabetes
Basalin · Phase 3 Type 2 diabetes mellitus
Conference Updates and Highlights
Learn about the latest updates from Gan & Lee Pharmaceuticals at international academic conferences
-
October 2, 2026
EASD 2026 Highlights | Pivotal Phase 3 SUPER-1 and SUPER-2 Studies of Once-Weekly Insulin ludefen Presented at EASD 2026, Demonstrating Superior Glycaemic Efficacy Compared to Once-Daily Basal Insulin
The 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD 2026) was held in Milan, Italy, on September 28, 2026. At this year's congress, Gan & Lee Pharmaceuticals showcased new clinical results for insulin ludefen, its investigational once-weekly basal insulin, underscoring the company's continued progress in insulin innovation and its growing visibility within the global diabetes community.
Read More -
September 21, 2026
Gan & Lee Pharmaceuticals Enters Recombinant Human Albumin Drug Research Field; GLR1075 Injection Receives Clinical Trial Approval
September 18, 2026 — Gan & Lee Pharmaceuticals (hereinafter referred to as "Gan & Lee Pharmaceuticals"; stock code: 603087.SH) announced that its independently developed recombinant human albumin GLR1075 Injection has officially received Investigational New Drug (IND) approval from the National Medical Products Administration (NMPA). It is intended for the treatment of cirrhotic ascites with hypoalbuminemia.
Read More -
September 7, 2026
Gan & Lee Pharmaceuticals' Once-Weekly Oral Peptide GLP-1RA GZC8072 Tablets Approved for Clinical Trials
Beijing, August 24, 2026 – Gan & Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as "Gan & Lee," Stock Code: 603087.SH) announced today that GZC8072 Tablets, a Class 1 innovative therapeutic biological product independently developed by its wholly-owned subsidiary, Gan & Lee Pharmaceuticals (Shandong) Co., Ltd., with proprietary intellectual property rights, has officially received clinical trial approval from the National Medical Products Administration (NMPA) for weight management in obese or overweight individuals. The drug is an ultra-long-acting peptide analogue developed based on native glucagon-like peptide-1 (GLP-1), with the potential to offer patients a more convenient treatment option through a once-weekly oral administration regimen.
Read More